title: Contribution of prothrombin 20210A allele and factor V Leiden mutation to thrombosis risk in thrombophilic families with other hemostatic deficiencies.
abstract: OBJECTIVE
  The aims of this study were to compare the lifetime probability of developing thrombosis in 722 relatives of 132 thrombophilic families of symptomatic probands with recognized thrombophilic defects and to determine the prevalence of the factor V Leiden (FVL) mutation and the 20210A allele of the prothrombin gene (PT20210A) in these families.
  
  
  METHODS
  The study included 722 members belonging to 132 unrelated families. The propositi were patients who had been referred to our Thrombosis Unit. The families were selected through a symptomatic proband. Once a patient with a deficiency or mutation was identified, family members were screened for the same defect.
  
  
  RESULTS
  The prevalence of FVL and PT20210A in families with other thrombophilic defects was higher than expected. Compared with non-deficient individuals, the risk of venous thrombosis was increased in subjects with antithrombin (AT), protein S (PS) and protein C (PC) deficiencies, and in carriers of FVL and PT20210A mutations. The risk of thrombosis was significantly increased for individuals with combined genetic defects (PC-FVL, PS-FVL, PS-PT20210A and FVL-PT20210A). The ages at the time of 50% thrombosis-free survival were as follows: 34 years for AT deficiency, (19 years with FVL, 21 years with PT20210A), 62 years for PC deficiency (33 years with FVL, 44 years with PT20210A), 37 years for PS deficiency (24 years with FVL, 36 years with PT20210A), 50 years for the FVL mutation (52 years with PT20210A), and 65 years for the PT20210A mutation. As for clinical characteristics, no differences were observed except for the higher frequency of oral contraceptive-related thrombosis in women who were carriers of PT20210A or FVL.
  
  
  CONCLUSIONS
  Based on these results, screening for FVL and PT20210A mutation is recommended in patients with other thrombophilic defects. To the best of our knowledge, this is the first family study, including the PT20210A mutation, that compares genetic risk factors for thrombosis and the lifelong probability of developing thrombosis.
authors.affiliation: Thrombosis and Hemostasis Unit, Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Tirado
authors.forename: J
authors.initials: J
authors.lastname: Mateo
authors.forename: J M
authors.initials: JM
authors.lastname: Soria
authors.forename: A
authors.initials: A
authors.lastname: Oliver
authors.forename: M
authors.initials: M
authors.lastname: Borrell
authors.forename: I
authors.initials: I
authors.lastname: Coll
authors.forename: C
authors.initials: C
authors.lastname: Vallvé
authors.forename: J C
authors.initials: JC
authors.lastname: Souto
authors.forename: E
authors.initials: E
authors.lastname: Martínez-Sánchez
authors.forename: J
authors.initials: J
authors.lastname: Fontcuberta
mesh_terms: D000293:Adolescent; D000328:Adult; D000483:Alleles; D005165:Factor V / Q000235:genetics*; D005192:Family Health; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016017:Odds Ratio; D011516:Prothrombin / Q000235:genetics*; D012307:Risk Factors; D019851:Thrombophilia / Q000150:complications / Q000235:genetics; D013927:Thrombosis / Q000235:genetics*
chemical_list: C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin